ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.96
0.71%
US Tech 100
20,762.73
1.73%
S&P 500
5,942.47
1.26%
US Dollar vs CAD
1.44457
0.00%
Bitcoin
97,886.39
-0.33%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Italy
  5. BIT

  6. Ageas SA NV (1AGS) Share Price

Ageas SA NV

Ageas SA NV (1AGS)

BIT
46.96
0.34
(0.73%)
Closed January 05 10:30AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
46.96
Bid
46.96
Ask
47.44
Volume
100
46.96 Day's Range 47.18
37.49 52 Week Range 52.40
Market Cap
8.827B
Previous Close
46.62
Open
47.18
Last Trade
40
@
46.96
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
315
Shares Outstanding
187,971,187
Dividend Yield
6.92%
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
5.63B
Net Profit
953M

About Ageas SA NV

Sector
Fire, Marine, Casualty Ins
Industry
Fire, Marine, Casualty Ins
Website
www.ageas.com
Headquarters
Brussels, Brussels-capital Region, Bel
Founded
-
Ageas SA NV is listed in the Fire, Marine, Casualty Ins sector of the Italian Stock Exchange with ticker 1AGS. The last closing price for Ageas SA NV was 46.62 €. Over the last year, Ageas SA NV shares have traded in a share price range of 37.49 € to 52.40 €.

Ageas SA NV currently has 187,971,187 shares outstanding. The market capitalization of Ageas SA NV is 8.76 € billion.

Ask ADVFN Intelligence (AI)

1AGS Latest News

More News

Rapport d’Ageas sur le programme de rachat d’actions

Rapport d’Ageas sur le programme de rachat d’actions Dans le cadre du programme de rachat d’actions annoncé le 28 août 2024, Ageas indique que 21.749 actions Ageas ont été achetées durant la...

December 30 2024
UK Regulatory

Ageas reports on the progress of share buy-back programme

Ageas reports on the progress of share buy-back programme Further to the initiation of the share buy-back programme announced on 28 August 2024, Ageas reports the purchase of 21,749 Ageas shares...

December 30 2024
UK Regulatory

Rapport d’Ageas sur le programme de rachat d’actions

Rapport d’Ageas sur le programme de rachat d’actions Dans le cadre du programme de rachat d’actions annoncé le 28 août 2024, Ageas indique que 50.094 actions Ageas ont été achetées durant la...

December 23 2024
UK Regulatory

Ageas reports on the progress of share buy-back programme

Ageas reports on the progress of share buy-back programme Further to the initiation of the share buy-back programme announced on 28 August 2024, Ageas reports the purchase of 50,094 Ageas shares...

December 23 2024
UK Regulatory

Ageas and The Goldman Sachs Group, Inc:  Transparency notification

Ageas and The Goldman Sachs Group, Inc:  Transparency notification In accordance with the rules on financial transparency*, The Goldman Sachs Group, Inc has notified Ageas on 13 December 2024...

December 17 2024
UK Regulatory

Ageas et The Goldman Sachs Group, Inc: Notification de transparence

Ageas et The Goldman Sachs Group, Inc: Notification de transparence Conformément aux règles de transparence financière*, The Goldman Sachs Group, Inc a introduit le 13 décembre 2024 une...

December 17 2024
UK Regulatory

Rapport d’Ageas sur le programme de rachat d’actions

Rapport d’Ageas sur le programme de rachat d’actions Rapport d’Ageas sur le programme de rachat d’actions Dans le cadre du programme de rachat d’actions annoncé le 28 août 2024, Ageas indique que...

December 16 2024
UK Regulatory

Ageas reports on the progress of share buy-back programme

Ageas reports on the progress of share buy-back programme Ageas reports on the progress of share buy-back programme Further to the initiation of the share buy-back programme announced on 28 August...

December 16 2024
UK Regulatory

Ageas atteint un accord avec Saga, le spécialiste britannique des plus de 50 ans

Ageas atteint un accord avec Saga, le spécialiste britannique des plus de 50 ans Ageas atteint un accord avec Saga, le spécialiste britannique des plus de 50 ans Ageas annonce aujourd’hui avoir...

December 16 2024
UK Regulatory

Ageas reaches agreement with UK over 50s specialist Saga

Ageas reaches agreement with UK over 50s specialist Saga Ageas reaches agreement with UK over 50s specialist Saga Ageas announces today that it has successfully concluded the exclusive...

December 16 2024
UK Regulatory
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.881.9097222222246.0848.6646.0831946.30094044DE
4-0.9-1.8804847471847.8648.6645.5431846.76991274DE
12-1.94-3.967280163648.952.445.5431548.21912215DE
264.049.41286113742.9252.440.529847.28881436DE
527.4418.825910931239.5252.437.4939344.14508306DE
1561.022.220287331345.9452.433.7535642.58046393DE
260-5.92-11.195158850252.8853.925.2434140.79176762DE

1AGS - Frequently Asked Questions (FAQ)

What is the current Ageas SA NV share price?
The current share price of Ageas SA NV is 46.96 €
How many Ageas SA NV shares are in issue?
Ageas SA NV has 187,971,187 shares in issue
What is the market cap of Ageas SA NV?
The market capitalisation of Ageas SA NV is EUR 8.76B
What is the 1 year trading range for Ageas SA NV share price?
Ageas SA NV has traded in the range of 37.49 € to 52.40 € during the past year
What is the reporting currency for Ageas SA NV?
Ageas SA NV reports financial results in EUR
What is the latest annual turnover for Ageas SA NV?
The latest annual turnover of Ageas SA NV is EUR 5.63B
What is the latest annual profit for Ageas SA NV?
The latest annual profit of Ageas SA NV is EUR 953M
What is the registered address of Ageas SA NV?
The registered address for Ageas SA NV is MANHATTAN CENTER BRUXELLES, AVENUE DU BOULEVARD 21, BRUSSELS, BRUSSELS-CAPITAL REGION, 1210
What is the Ageas SA NV website address?
The website address for Ageas SA NV is www.ageas.com
Which industry sector does Ageas SA NV operate in?
Ageas SA NV operates in the FIRE, MARINE, CASUALTY INS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WAMB26Ambromobiliare SpA
0.098 €
(96.00%)
53.83k
1NBNorthern Data AG
52.50 €
(30.76%)
34
EVAAskoll Eva SPA
0.17 €
(25.46%)
403k
WSOGESWarr Soges Group
0.115 €
(21.05%)
15k
WTFINTrevi Finanziaria Industriale Spa
0.89 €
(18.67%)
3.33k
WCOSMOFarmacosmo spa
0.0096 €
(-67.89%)
6.67k
COSMOFarmacosmo spa
0.668 €
(-22.86%)
338.93k
WTWL26TraWell Co SpA
0.22 €
(-21.43%)
600
GTGT Talent Group SpA
2.76 €
(-14.29%)
21.38k
WSGC28SG Company SpA
0.025 €
(-12.89%)
12.26k
TITTelecom Italia SpA
0.243 €
(-2.68%)
128.24M
ISPIntesa Sanpaolo Spa
3.849 €
(-0.03%)
47.15M
SPMSaipem Spa
2.717 €
(2.07%)
44.36M
ENELEnel Spa
7.023 €
(-0.03%)
14.4M
BPEBper Banca SPA
5.90 €
(-0.94%)
11.78M

Discussion

View Full Feed
boi568 boi568 7 minutes ago
That spike to $31.50 was not organic and it was clearly generated by a big player. I have always thought it was an engineered mini-short squeeze.
AVXL
Mr. Bill Mr. Bill 19 minutes ago
https://www.goodrx.com/well-being/sleep/how-to-sleep-with-sciatica
nowwhat2 nowwhat2 21 minutes ago
Could still just be climbing in sympathy w overall crypto mkt

Scathingly poor outlooks

https://www.youtube.com/watch?v=EOsjnOUAw14



https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg

WONDF
DonVance DonVance 22 minutes ago
This will hit 1k this year I believe now.
MSTR
georgejjl georgejjl 23 minutes ago
How many of the 7 million Alzheimer’s patients in the USA are projected to be treated with the MAB infusions during 2025???

How many people with Alzheimer’s in the USA are projected to be treated with donepezil (Aricept) or memantine during 2025???

The treatment used t
AVXL
Mr. Bill Mr. Bill 24 minutes ago
Stretches https://www.healthline.com/health/back-pain/sciatic-stretches#sitting-spinal-stretch
Graniteguy Graniteguy 25 minutes ago
Doc and Investor posters here tend to be negatively biased which you whole heartedly champion, especially "Doc" who's medical opinion is at best questionable, and incredibly biased, to fit a narrative of constant failure for Anavex's Blarcamesine. The fact that you pile onto their "steaming pile of
AVXL
BDEZ BDEZ 27 minutes ago
The Russes hit the jackpot?
BDEZ BDEZ 28 minutes ago
40% of homicides in the US take place in districts with a Soros-funded prosecutor.

Biden gave him a Medal Of Freedom.

https://x.com/EndWokeness/status/1875725808071012529
BDEZ BDEZ 28 minutes ago
Not good, thanks for sharing.
sand sand 35 minutes ago
Thank you Ducci for all your sharing and insights extremely helpful. I'm slowly diligently getting there rewiring the brain and focusing on what shows the moves. Much continued success this week. Thank you again.
SPY
mining101 mining101 36 minutes ago
Moving hard soon 
EFSH
mining101 mining101 37 minutes ago
Superb
MEGL
benz280c benz280c 44 minutes ago
Speak louder and maybe you will convince somebody that this is how you really feel. No need to be insecure around your fellow investors.
GDVM
rx7171 rx7171 51 minutes ago
In addition MABs are approved for only a limited portion of the AD population, whereas Blarcamasine appears to be effective in 70-80% of the ITT population with its strongest efficacy in the 70% with wild type Sigma-1.
AVXL
TheHound TheHound 52 minutes ago
Learn how to use the bull market support band with that chart and you’ll have a powerful tool under your belt!
XRPUSD
Investor2014 Investor2014 55 minutes ago
When I say that the totality of information is what Anavex rely on it does take into account the pretty ineffective SOC, associated risks and inconveniences for patients.

Still any drug regulatory process must and should look carefully at the data to ensure that neither type one or tw
AVXL
nowwhat2 nowwhat2 1 hour ago
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
BTCUSD
rx7171 rx7171 1 hour ago
Yes that spike to $23 in June of 2021 was driven entirely by the excellent Phase II data for PDD.

Yet now after completing the AD 2b/3 trial and having an EMA MAA accepted for evaluation the share price is barely half that number!

I understand the company being very ca
PDD
sunspotter sunspotter 1 hour ago
Black Cat Moan was one of my favorites back in the day:

https://youtu.be/cxN-frB1UbI?si=Ph6XMC3omR0rRlmR

Edit: auto correct changed Moan to Moana. The cultural prevalence of Disney.
Investor2014 Investor2014 1 hour ago
The ex-biotech executive is back in the Rett trap posting mode - hope it goes better with the biased approach this time.

Listing all the site PI’s is not world class peer review WGT confirmation.
AVXL
nowwhat2 nowwhat2 1 hour ago
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
sunspotter sunspotter 1 hour ago
I rather think you missed the point. It’s not that higher doses of GALT’s drug are toxic, it’s that they are ineffective.

Given the purported mechanism, that almost certainly means lower doses are too, and that the implication that the lower dose worked is merely an artefact.
GALT

Your Recent History

BIT
1AGS
Ageas SA NV
TG
A1VE52
Republic of Hungary
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads